Biotech billionaire Hiroshi ‘Mickey’ Mikitani doubles down on quest to build a pharma company, closing round at $284M
The latest billionaire to be drawn into the biotech game is doubling down on his California startup with plans to vault it into position as a new-wave pharma company.
Hiroshi “Mickey” Mikitani has contributed to an add-on $134 million tranche for the C round backing Rakuten Aspyrian. That brings the round to $284 million, much of which came directly from the fabulously wealthy Japanese e-tailer.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.